Welcome to our dedicated page for Onco-Innovations news (Ticker: ONNVF), a resource for investors and traders seeking the latest updates and insights on Onco-Innovations stock.
News for Onco-Innovations Limited (ONNVF) centers on its activities in oncology research, preclinical drug development, AI-enabled precision medicine, and corporate financing. The company describes itself as a Canadian-based oncology-focused organization with an exclusive worldwide license to patented technology targeting solid tumours, including its PNKP Inhibitor Technology platform.
Investors and observers following Onco-Innovations’ news can expect updates on the advancement of its PNKP Inhibitor Technology (A83B4C63), including manufacturing milestones with Dalton Pharma Services such as process optimization, intermediate scale-up, analytical method development, and preparation for potential future clinical material production. Releases also cover collaborations with partners like Kuano Ltd., where quantum-ready molecular modelling and AI-driven compound design are being applied to deepen understanding of PNKP inhibition and guide next-generation therapeutic candidates.
Another important stream of news involves Onco-Innovations’ subsidiary Inka Health and its SynoGraph platform. Announcements have highlighted publications on the transportability of real-world evidence, integration of advanced statistical methods into SynoGraph, and participation in precision oncology forums with organizations such as Colorectal Cancer Canada. These items illustrate how the company links AI, real-world data, and oncology decision-making.
Corporate and capital markets developments also feature in the news flow. Onco-Innovations has reported private placements, board appointments, marketing engagements, and its intention to pursue a potential Nasdaq cross-listing with the support of a U.S. investment bank. For a consolidated view of these scientific, strategic, and financing updates, this news page provides a single location to review the company’s disclosed developments over time.
Onco-Innovations (OTCQB:ONNVF) has initiated manufacturing activities with Dalton Pharma Services for its proprietary nanoparticle formulation, PEO-b-PBz-CL. This formulation is a crucial component of Onco's drug delivery platform designed to work with their PNKP inhibitor.
The manufacturing process will involve scale-up activities from 10 grams to 350 grams, focusing on optimization and establishing reproducible synthesis methods. Dalton will ensure the formulation meets quality specifications for purity, molecular weight, and residual solvent levels, while generating necessary analytical data for regulatory filings and future GMP manufacturing.
Onco-Innovations (OTCQB:ONNVF) announced that its subsidiary, Inka Health Corp., will chair and lead the fourth roundtable of Colorectal Cancer Canada's (CRC) Catalysts: Innovating for Tomorrow Series this fall. The virtual event will focus on data innovation and digital trust in oncology.
The roundtable will be chaired by Dr. Paul Arora, with expert speakers including Dr. Steve Jones from BC Cancer, Dr. Winson Cheung from the University of Calgary, and Inka Health Co-Founder Alind Gupta. The discussion will explore the integration of artificial intelligence, secure data sharing, and the application of emerging data sources in precision medicine.
Onco-Innovations (CBOE CA:ONCO) has appointed Dr. John Mackey, Professor Emeritus in Oncology at the University of Alberta, to its Scientific and Clinical Advisory Board. Dr. Mackey brings extensive experience in oncology, clinical trials, and drug development, having previously served as Director of the Clinical Trial Unit at Cross Cancer Institute and Executive Director of TRIO.
Dr. Mackey's credentials include co-founding Pacylex Pharmaceuticals, serving as CEO of illumiSonics, holding 12 patents, and co-authoring over 300 peer-reviewed publications. His expertise will support Onco's PNKP inhibitor program development, particularly in clinical strategy and trial methodology.
Onco-Innovations (OTCQB:ONNVF) has announced that over 90% of its $0.60 common share purchase warrants have been successfully exercised over an eight-month period. This high conversion rate has resulted in additional capital inflow for the company through non-dilutive financing.
CEO Thomas O'Shaughnessy highlighted that the significant warrant exercise rate demonstrates strong shareholder confidence in the company's strategic direction and validates their ability to generate internal capital.
Onco-Innovations (OTCQB:ONNVF) has successfully closed its previously announced non-brokered private placement, raising $400,000 through the issuance of 243,903 units at $1.64 per unit. Each unit comprises one common share and one warrant, with warrants exercisable at $2.05 per share until August 13, 2028.
The company will utilize the proceeds for general corporate and working capital purposes, including operational and R&D objectives. Additionally, 2,439 administrative shares were issued to a third party for services related to the placement. All securities are subject to a four-month hold period ending December 14, 2025.
Onco-Innovations (OTCQB:ONNVF) has signed a Start-Up Agreement with Avance Clinical to prepare for its first-in-human trial of their novel PNKP inhibitor therapy. The agreement focuses on developing crucial regulatory and clinical documentation required for human testing approvals.
Under the partnership, Avance will provide comprehensive support including: development of an Investigator's Brochure, creation of clinical trial protocols, conducting nonclinical gap analysis, and preparation for a pre-IND meeting with the FDA. The therapy targets advanced-stage cancers with PTEN1 or SHP-12 deficiency.
Onco-Innovations Limited (OTCQB:ONNVF) announced that its subsidiary Inka Health has been selected by OneMedNet (Nasdaq:ONMD) to lead an AI-driven oncology data analytics initiative. The project aims to develop external control arms (ECAs) using OneMedNet's regulatory-grade patient data to accelerate cancer therapy development.
The collaboration will utilize Inka Health's SynoGraph platform to validate an ECA for the Keynote-189 trial of pembrolizumab in non-small cell lung cancer. This initiative targets the Real-World Evidence (RWE) market, projected to reach $4.6 billion by 2030. The project aims to demonstrate how real-world data can replicate traditional clinical trial results more efficiently, potentially reducing development costs and timelines.
The companies plan to submit their findings to ISPOR Europe 2025, positioning themselves at the forefront of AI-driven oncology research and drug development.
Onco-Innovations (OTCQB:ONNVF) has announced a non-brokered private placement to raise up to $400,000 through the issuance of 243,903 units at $1.64 per unit. Each unit includes one common share and one warrant, with warrants exercisable at $2.05 for 36 months.
The company will issue additional shares as a 1% administrative fee to a third party. Additionally, Onco-Innovations has approved the grant of 119,785 stock options and 960,000 restricted share units (RSUs) under its equity incentive plan. The proceeds will support general corporate purposes and R&D objectives.
Onco-Innovations (CBOE CA:ONCO) has appointed renowned chemist Dr. Dennis Hall to its Scientific and Clinical Advisory Board. Dr. Hall, a Professor of Chemistry at the University of Alberta and Tier 1 Canada Research Chair in Boron Chemistry, brings extensive expertise in organoboron chemistry, catalysis, and medicinal chemistry.
Dr. Hall's impressive credentials include over 175 peer-reviewed publications, 18,000+ citations, and numerous prestigious awards. He will provide strategic guidance on the company's R&D initiatives, particularly focusing on the development of PNKP Inhibitor Technology NP/A83 for oncology applications.
Onco-Innovations (OTCQB:ONNVF) has entered into a services agreement with Redwood AI to advance the development of its exclusively-licensed Polynucleotide Kinase Phosphatase (PNKP) Compound technology. The collaboration aims to enhance the company's drug development capabilities through AI-driven chemistry tools.
The partnership will leverage Redwood AI's expertise in synthesis evaluation, cheminformatics, and organ-specific toxicity prediction for the PNKP technology. The proprietary compound targets solid tumors by increasing sensitivity to radiation and DNA-damaging chemotherapies. This strategic collaboration is designed to support Onco's progression toward First-in-Human studies by improving scalability, safety, and discovery precision.